IRBM, Merck Research Laboratories, Via Pontina Km 30600, 00040, Pomezia (RM), Italy.
Drug Deliv. 2010 May;17(4):214-22. doi: 10.3109/10717541003667814.
The purpose of this study was to investigate the in vivo absorption enhancement of a nucleoside (phosphoramidate prodrug of 2'-methyl-cytidine) anti-viral agent of proven efficacy by means of intestinal permeation enhancers. Natural nucleosides are hydrophilic molecules that do not rapidly penetrate cell membranes by diffusion and their absorption relies on specialized transporters. Therefore, the oral absorption of nucleoside prodrugs and the target organ concentration of the biologically active nucleotide can be limited due to poor permeation across the intestinal epithelium. In the present study, the specificity, concentration dependence, and effect of four classes of absorption promoters, i.e. fatty acids, steroidal detergents, mucoadhesive polymers, and secretory transport inhibitors, were evaluated in a rat in vivo model. Sodium caprate and alpha-tocopheryl-polyethyleneglycol-1000-succinate (TPGS) showed a significant effect in increasing liver concentration of nucleotide (5-fold). These results suggested that both excipients might be suited in a controlled release matrix for the synchronous release of the drug and absorption promoter directly to the site of absorption and highlights that the effect is strictly dependent on the absorption promoter dose. The feasibility of such a formulation approach in humans was evaluated with the aim of developing a solid dosage form for the peroral delivery of nucleosides and showed that these excipients do provide a potential valuable tool in pre-clinical efficacy studies to drive discovery programs forward.
本研究旨在通过肠道渗透增强剂研究一种已证实具有疗效的核苷(2'-甲基胞苷的磷酰胺酯前药)抗病毒药物的体内吸收增强作用。天然核苷是亲水分子,不能通过扩散快速穿透细胞膜,其吸收依赖于专门的转运体。因此,由于跨肠上皮的渗透性差,核苷前药的口服吸收和生物活性核苷酸的靶器官浓度可能受到限制。在本研究中,在大鼠体内模型中评估了四类吸收促进剂,即脂肪酸、甾体洗涤剂、粘膜粘附聚合物和分泌转运抑制剂的特异性、浓度依赖性和作用。月桂酸钠和α-生育酚聚乙二醇-1000-琥珀酸酯(TPGS)显著增加了核苷酸在肝脏中的浓度(增加了 5 倍)。这些结果表明,这两种赋形剂都可能适用于控释基质,用于将药物和吸收促进剂直接释放到吸收部位,这突出表明这种作用严格依赖于吸收促进剂的剂量。还评估了这种制剂方法在人体中的可行性,目的是开发一种用于口服递送核苷的固体制剂,结果表明这些赋形剂确实为临床前疗效研究提供了一种有价值的潜在工具,以推动发现计划的进展。